Vitamin D concentrations in familial combined hyperlipidemia: Effects of lipid lowering treatment

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Miñambres, Inka ^a,b   Sánchez Quesada, Jose Luis ^c   Sánchez Hernández, Joan ^d   Rodríguez, Jose ^a,c   De Leiva, Alberto ^a,b,c,e   Pérez, Antonio ^a,b,c,d  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Dyslipidemia; Familial combined hyperlipidemia; Insulin resistance; Metabolic syndrome; Vitamin D

Indexed keywords

EID: 84892631029     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-7     Document Type: Article

References (40)

1. Vitamin D, cardiovascular disease and mortality. Pilz S, Tomaschitz A, Marz W, Drechsler C, Ritz E, Zittermann A, Cavalier E, Pieber TR, Lappe JM, Grant WB, Holick MF, Dekker JM, Clin Endocrinol (Oxf) 2011 75 5 575 584 10.1111/j.1365-2265.2011.04147.x 21682758
2. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: ameta-analysis of prospective studies. Wang L, Song Y, Manson JE, Pilz S, März W, Michaëlsson K, Lundqvist A, Jassal SK, Barrett-Connor E, Zhang C, Eaton CB, May HT, Anderson JL, Sesso HD, Circ Cardiovasc Qual Outcomes 2012 5 6 819 829 10.1161/CIRCOUTCOMES.112.967604 23149428
3. Low levels of serum 25-hydroxyvitamin D are associated with increased risk of myocardial infarction, especially in women: results from the MONICA/KORA Augsburg case-cohort study. Karakas M, Thorand B, Zierer A, Huth C, Meisinger C, Roden M, Rottbauer W, Peters A, Koenig W, Herder C, J Clin Endocrinol Metab 2013 98 1 272 280 10.1210/jc.2012-2368 23150690
4. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Forman JP, Curhan GC, Taylor EN, Hypertension 2008 52 5 828 832 10.1161/HYPERTENSIONAHA.108.117630 18838623
5. Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants. Kunutsor SK, Apekey TA, Steur M, Eur J Epidemiol 2013 28 3 205 221 10.1007/s10654-013-9790-2 23456138
6. Vitamin D and type 2 diabetes: a systematic review. Mitri J, Muraru MD, Pittas AG, Eur J Clin Nutr 2011 65 9 1005 1015 10.1038/ejcn.2011.118 21731035
7. Low 25-hydroxyvitamin D and risk of type 2 diabetes: a prospective cohort study and metaanalysis. Afzal S, Bojesen SE, Nordestgaard BG, Clin Chem 2013 59 2 381 391 10.1373/clinchem.2012.193003 23232064
8. Circulating 25-hydroxyvitamin D concentration and the risk of type 2 diabetes: results from the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort and updated meta-analysis of prospective studies. Forouhi NG, Ye Z, Rickard AP, Khaw KT, Luben R, Langenberg C, Wareham NJ, Diabetologia 2012 55 8 2173 2182 10.1007/s00125-012-2544-y 22526608
9. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Jorde R, Grimnes G, Prog Lipid Res 2011 50 4 303 312 10.1016/j.plipres.2011.05.001 21640757
10. Unchanged hypovitaminosis D and secondary hyperparathyroidism in morbid obesity after bariatric surgery. Ybarra J, Sanchez-Hernandez J, Gich I, De Leiva A, Rius X, Rodríguez-Espinosa J, Pérez A, Obes Surg 2005 15 3 330 335 10.1381/0960892053576758 15826464 (Pubitemid 40463597)
11. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Ford ES, Ajani UA, McGuire LC, Liu S, Diabetes Care 2005 28 5 1228 1230 10.2337/diacare.28.5.1228 15855599 (Pubitemid 40616645)
12. The association of hypovitaminosis d with the metabolic syndrome is independent of the degree of obesity. Minambres I, Sanchez-Hernandez J, Sanchez-Quesada JL, Rodríguez J, de Leiva A, Pérez A, ISRN Endocrinol 2012 2012 691803 23150833
13. Vitamin D intake and status are associated with lower prevalence of metabolic syndrome in U.S. adults: National Health and Nutrition Examination Surveys 2003-2006. Maki KC, Fulgoni VL 3rd, Keast DR, Rains TM, Park KM, Rubin MR, Metab Syndr Relat Disord 2012 10 5 363 372 10.1089/met.2012.0020 22793651
14. European Male Ageing Study Group: Vitamin D, parathyroid hormone and the metabolic syndrome in middle-aged and older European men. Lee DM, Rutter MK, O'Neill TW, Boonen S, Vanderschueren D, Bouillon R, Bartfai G, Casanueva FF, Finn JD, Forti G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Pendleton N, Punab M, Silman AJ, Wu FC, Eur J Endocrinol 2009 161 6 947 954 10.1530/EJE-09-0496 19773367
15. Vitamin D and hyperparathyroidism in obesity. Grethen E, McClintock R, Gupta CE, Jones R, Cacucci BM, Diaz D, Fulford AD, Perkins SM, Considine RV, Peacock M, J Clin Endocrinol Metab 2011 96 5 1320 1326 10.1210/jc.2010-2202 21325456
16. Influence of obesity on plasma lipoproteins, glycaemia and insulinaemia in patients with familial combined hyperlipidaemia. Ascaso JF, Sales J, Merchante A, Real J, Lorente R, Martinez-Valls J, Carmena R, Int J Obes Relat Metab Disord 1997 21 5 360 366 10.1038/sj.ijo.0800413 9152737 (Pubitemid 27190187)
17. Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemia? Karjalainen L, Pihlajamaki J, Karhapaa P, Laakso M, Arterioscler Thromb Vasc Biol 1998 18 10 1548 1553 10.1161/01.ATV.18.10.1548 9763525 (Pubitemid 28465405)
18. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Hokanson JE, Austin MA, Zambon A, Brunzell JD, Arterioscler Thromb 1993 13 3 427 434 10.1161/01.ATV.13.3.427 8443147 (Pubitemid 23075633)
19. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB, J Lipid Res 1983 24 2 147 155 6403642 (Pubitemid 13080348)
20. Lipid profile of the Spanish population: the DRECE (diet and risk of cardiovascular disease in Spain) study. DRECE study group. Gomez-Gerique JA, Gutierrez-Fuentes JA, Montoya MT, Porres A, Rueda A, Avellaneda A, Rubio MA, Med Clin (Barc) 1999 113 19 730 735 10680124
21. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Friedewald WT, Levy RJ, Fredrickson DS, Clin Chem 1972 18 6 499 502 4337382
22. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). National Cholesterol Education Program (NCEP), Circulation 2002 106 25 3143 3421 12485966
23. Density distribution of electronegative LDL in normolipemic and hyperlipemic subjects. Sanchez-Quesada JL, Benitez S, Otal C, Franco M, Blanco-Vaca F, Ordóñez-Llanos J, J Lipid Res 2002 43 5 699 705 11971940 (Pubitemid 34477896)
24. Cardiovascular risk in subjects with high probability of metabolic syndrome and insulin resistance. DESIRE study. Goday A, Gabriel R, Ascaso JF, Franch J, Ortega R, Martínez O, Lenores N, DESIRE study, Rev Clin Esp 2008 208 8 377 385 10.1157/13126339 18817695
25. Sleeve gastrectomy and Roux-en-Y gastric bypass are equally effective in correcting insulin resistance. Benaiges D, Flores Le-Roux JA, Pedro-Botet J, Chillarón JJ, Renard M, Parri A, Ramon JM, Pera M, Goday A, Int J Surg 2013 11 4 309 313 10.1016/j.ijsu.2013.02.007 23462580
26. Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Hollis BW, Am J Clin Nutr 2008 88 2 507S 510S 18689391
27. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. Hollis BW, J Nutr 2005 135 2 317 322 15671234 (Pubitemid 40194499)
28. Iatropathogenic effect of Mevacor on vitamin D metabolism. Wilczek H, Sobra J, Justova V, Ceska R, Jůzová Z, Procházková R, Kvasilová M, Pacovský V, Cas Lek Cesk 1989 128 40 1254 1256 2582470 (Pubitemid 19240450)
29. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Melamed ML, Michos ED, Post W, Astor B, Arch Intern Med 2008 168 15 1629 1637 10.1001/archinte.168.15.1629 18695076
30. Plasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese individuals. Lu L, Yu Z, Pan A, Hu FB, Franco OH, Li H, Li X, Yang X, Chen Y, Lin X, Diabetes Care 2009 32 7 1278 1283 10.2337/dc09-0209 19366976
31. Vitamin D may not improve lipid levels: a serial clinical laboratory data study. Ponda MP, Huang X, Odeh MA, Breslow JL, Kaufman HW, Circulation 2012 126 3 270 277 10.1161/CIRCULATIONAHA.111.077875 22718799
32. Plasma vitamin D and parathormone are associated with obesity and atherogenic dyslipidemia: a cross-sectional study. Guasch A, Bullo M, Rabassa A, Bonada A, Del Castillo D, Sabench F, Salas-Salvadó J, Cardiovasc Diabetol 2012 11 149 10.1186/1475-2840-11-149 23228198
33. Statin but not non-statin lipid-lowering drugs decrease fracture risk: a nation-wide case-control study. Rejnmark L, Vestergaard P, Mosekilde L, Calcif Tissue Int 2006 79 1 27 36 10.1007/s00223-006-0024-4 16868664 (Pubitemid 44198289)
34. Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Perez-Castrillon JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, Dueñas A, Am J Cardiol 2007 99 7 903 905 10.1016/j.amjcard. 2006.11.036 17398180 (Pubitemid 46483276)
35. STATIN-D Study: Comparison of the Influences of Rosuvastatin and Fluvastatin Treatment on the Levels of 25 Hydroxyvitamin D. Ertugrul DT, Yavuz B, Cil H, Ata N, Akin KO, Kucukazman M, Yalcin AA, Dal K, Yavuz BB, Tutal E, Cardiovasc Ther 2011 29 2 146 152 10.1111/j.1755-5922.2010.00141.x 20370794
36. Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat: role of vitamin D metabolites. Beltowski J, Atanassova P, Chaldakov GN, Jamroz-Wiśniewska A, Kula W, Rusek M, Atherosclerosis 2011 219 2 526 531 10.1016/j.atherosclerosis.2011.08.009 21889144
37. Statins and vitamin D: editorial to: "increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins?" by Bunyamin Yavuz et al. Grimes DS, Cardiovasc Drugs Ther 2009 23 4 261 262 10.1007/s10557-009-6182-7 19618258
38. Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial. Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L, Int J Endocrinol 2010 2010 957174 20016680
39. Effect of Simvastatin/Ezetimibe 10/10 mg Versus Simvastatin 40 mg on Serum Vitamin D Levels. Liberopoulos EN, Makariou SE, Moutzouri E, Kostapanos MS, Challa A, Elisaf M, J Cardiovasc Pharmacol Ther 2013 18 3 229 233 10.1177/1074248412470513 23288870
40. Therapy with fibrates and vitamin D metabolism. Wilczek H, Sobra J, Ceska R, Justová V, Procházková R, Kvasilová M, Jůzová Z, Cas Lek Cesk 1993 132 20 630 632 8269466